Bellshill, Glasgow, 22nd February 2016 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on Lamellasome™ technology, today competes in the secondary stage of Pitch@Palace, an event for biotech entrepreneurs, founded by The Duke of York. Biotech companies going forward into this next round of Pitch@Palace will be given the opportunity to hear from leading industry experts and receive coaching and mentoring, as well as the opportunity to practice their pitches, in the ‘Bootcamp’-style event. From these competitors, judges must make the tough decision to pick 12-15 entrepreneurs to pitch their ideas to 300 potential investors, CEOs, Angels, Mentors and key business partners at the final Pitch@Palace event, which is set to place at St. James’s Palace, London on 7th March. Alec McLean, CEO of Lamellar Biomedical, said: “We are thrilled to have made it this far in Pitch@Palace. The Duke of York founded Pitch@Palace to support entrepreneurs like Lamellar with the amplification and acceleration of our business ideas by connecting us with potential supporters that can help our company continue to reach its full potential. Just to have reached this stage is a great honour, and we look forward to the next round.” Lamellar is developing a number of patent-protected medical devices and pharmaceuticals targeting Radiotherapy-Induced Xerostomia questionnaire (RIX), Dry Eye Disease and Cystic Fibrosis and is currently recruiting for a Clinical Study assessing Visco-ease for the treatment of RIX.